Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2017 (2017), Article ID 4802690, 5 pages
https://doi.org/10.1155/2017/4802690
Research Article

Bevacizumab (Avastin) and Thermal Laser Combination Therapy for Peripapillary Choroidal Neovascular Membranes

1Retina Consultants of Orange County, Fullerton, CA, USA
2The George Washington University School of Medicine and Health Sciences, Washington, DC, USA

Correspondence should be addressed to Sean D. Adrean

Received 17 December 2016; Accepted 20 February 2017; Published 26 March 2017

Academic Editor: Hyeong Gon Yu

Copyright © 2017 Sean D. Adrean et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. This is a retrospective interventional case series describing the results of 5 eyes from 5 patients with symptomatic peripapillary choroidal neovascularization (CNVM) receiving initial bevacizumab treatment followed by thermal laser and bevacizumab combination therapy. Methods. Patients received intravitreal bevacizumab injections until the lesions were well-defined. Thermal laser ablation was then administered and followed by an additional bevacizumab injection after one week. Visual outcomes, OCT changes, and rates of recurrence were recorded and analyzed. Results. Median visual outcomes improved from 20/50 to 20/30 (). Median central macular thickness decreased from 347 μm to 152 μm (). The mean visual improvement was 3 lines. An average of 3.8 bevacizumab injections per patient were given overall. Patients were followed for an average of 24 months, during which all eyes were absent for recurrence. Conclusion. Symptomatic peripapillary CNVM may be successfully managed with bevacizumab followed by a combination of thermal laser and bevacizumab without the need for frequent retreatment. The area requiring treatment may be better defined using bevacizumab, limiting the ablation of the healthy retina and improving treatment margins. With this treatment regimen, the patients experience improved visual outcomes and have a low rate of recurrence.